tirzepatide dose equivalent to semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are tirzepatide law office in west

Wegovy pill: first oral GLP-1 approved for weight loss In a landmark development, the FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025 , making it the worlds first oral GLP-1 receptor agonist approved specifically for weight management a major shift from the injection-only landscape [8]

For detailed reconstitution instructions, see our how to reconstitute peptides guide

Based on Lilly's precedent with tirzepatide, retatrutide will likely receive separate brand names for different indications: Tirzepatide became Mounjaro for type 2 diabetes and Zepbound for obesity Retatrutide is expected to follow the same pattern with distinct brand names per indication Brand names are typically announced closer to the FDA approval date or during the NDA review period

For current vendor pricing, see our Melanotan-1 and Melanotan-2 peptide pages with live price comparisons

Known as a triple agonist , the retatrutide peptide stimulates GLP-1, GIP, and glucagon receptors simultaneouslysomething no approved therapeutic currently does

How to Book Your Wegovy Consultation at Pure Medical Spa Getting started is simple and confidential